Dr. Drabick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 University Dr
Hershey, PA 17033Phone+1 717-531-6585Fax+1 717-531-0429
Summary
- Dr. Joseph Drabick is an oncologist in Hershey, PA and is affiliated with Penn State Milton S. Hershey Medical Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 34 years. He is experienced in immunotherapy, hematology, infectious diseases, oncology, and emergency medicine.
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1997 - 2000- National Capital ConsortiumFellowship, Infectious Disease, 1986 - 1988
- National Capital ConsortiumResidency, Internal Medicine, 1983 - 1986
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983
Certifications & Licensure
PA State Medical License 1986 - 2024
MD State Medical License 1989 - 2004- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Infectious Disease
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- FACP, FIDSI
- US Army Legion of Merit United States Army, 2004
Publications & Presentations
PubMed
- 200 citationsSD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyAntoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi
Cancer Discovery. 2018-01-01 - 402 citationsAcoustic separation of circulating tumor cellsPeng Li, Zhangming Mao, Zhangli Peng, Lanlan Zhou, Yuchao Chen
Proceedings of the National Academy of Sciences of the United States of America. 2015-04-21 - 14 citationsNeoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang
Clinical Cancer Research. 2021-03-22
Journal Articles
- Original Contribution Mitotic Activity in Non-Invasive Papillary Urothelial Carcinoma: Its Value in Predicting Tumor Recurrence, and Comparison to the Contemporary Two...Augustyna Gogoj, Suzanne B Merrill, Monika Joshi, Sheldon Holder, Joshua I Warrick, Matthew Kaag, Jay D Raman, Joseph Drabick, ScienceDirect
Press Mentions
Need for a Personalized Approach for Muscle Invasive Bladder Cancer: Role of Tumor Biology in Response to Neoadjuvant ChemotherapyDecember 4th, 2018
Metastatic Melanoma Patients May Benefit from Beta BlockersJanuary 22nd, 2018
Existing Drug May Improve Melanoma SurvivalJanuary 9th, 2018- Join now to see all
Professional Memberships
- Member
- Member
- Fellow
- Infectious Disease Society of AmericaFellow
- American Association for the Advancement of ScienceMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
